Abbvie Inc
NYSE:ABBV
Abbvie Inc
Interest Income Expense
Abbvie Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-13%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.6B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$172.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
Seagen Inc
NASDAQ:SGEN
|
Interest Income Expense
$51.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
22%
|
CAGR 10-Years
63%
|
See Also
What is Abbvie Inc's Interest Income Expense?
Interest Income Expense
-1.8B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Interest Income Expense amounts to -1.8B USD.
What is Abbvie Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-19%
Over the last year, the Interest Income Expense growth was 17%. The average annual Interest Income Expense growth rates for Abbvie Inc have been 8% over the past three years , -7% over the past five years , and -19% over the past ten years .